Simile M, Pascale R M, De Miglio M R, Nufris A, Daino L, Seddaiu M A, Muroni M R, Rao K N, Feo F
Istituto di Patologia Generale, Università di Sassari, Italy.
Int J Cancer. 1995 Jul 17;62(2):210-5. doi: 10.1002/ijc.2910620217.
Dehydroepiandrosterone (DHEA) inhibits the development of early pre-neoplastic lesions and prevents tumor development in various tissues when given to animals during the initiation/promotion stages of carcinogenesis. Our purpose was to evaluate whether DHEA can also arrest the growth and progression of late lesions, such as persistent nodules (PNs) of rat liver. Male F344 rats were subjected to initiation by diethylnitrosamine followed by selection according to the "resistant hepatocyte" (RH) protocol. Fifteen weeks after initiation, when PNs were present in the liver, the rats were fed a diet with/without 0.6% DHEA for a maximum of 15 weeks. Glucose-6-phosphate dehydrogenase (G6PD) activity was 17- to 20-fold higher in PNs than in normal liver 15-30 weeks after initiation. It significantly decreased, in both liver and PNs, 16 hr after starting DHEA feeding. Further DHEA feeding for 3-15 weeks decreased G6PD activity by 55-58% in both tissues. Eight weeks after starting DHEA, a fall in the proportion of labeled cells, after continuous contact with 3H thymidine for 7 days, was found in nodules. Treatment for 15 weeks with DHEA caused a marked decrease in the number of nodules per liver, as well as in the incidence of PNs with diameters of 3-6 and > 6 mm, respectively, while it did not affect PNs with diameters < 3 mm. Nodules showing patterns of malignant transformation were present in 40% of rats not treated with DHEA, but not in DHEA-treated rats. All of 8 surviving rats not treated with DHEA had carcinomas at the 56th week, while only 1 out of 4 surviving rats treated with DHEA had carcinoma. These data indicate that DHEA inhibits G6PD activity in rat liver and in PNs in vivo. This is associated with growth restraint of PNs and results in inhibition of their progression to malignancy.
脱氢表雄酮(DHEA)在致癌作用的起始/促进阶段给予动物时,可抑制早期癌前病变的发展,并防止各种组织中的肿瘤发生。我们的目的是评估DHEA是否也能阻止晚期病变(如大鼠肝脏的持续性结节,PNs)的生长和进展。雄性F344大鼠经二乙基亚硝胺启动,然后根据“抗性肝细胞”(RH)方案进行筛选。启动后15周,当肝脏中出现PNs时,将大鼠分别喂食含/不含0.6% DHEA的饮食,最长持续15周。启动后15 - 30周,PNs中的葡萄糖-6-磷酸脱氢酶(G6PD)活性比正常肝脏高17至20倍。开始喂食DHEA后16小时,肝脏和PNs中的G6PD活性均显著下降。进一步喂食DHEA 3至15周后,两个组织中的G6PD活性均降低了55 - 58%。开始喂食DHEA 8周后,在结节中发现连续接触3H胸腺嘧啶7天后标记细胞的比例下降。用DHEA治疗15周导致每只肝脏中的结节数量显著减少,以及直径为3 - 6 mm和> 6 mm的PNs的发生率分别显著降低,而对直径< 3 mm的PNs没有影响。未用DHEA治疗的大鼠中有40%出现了显示恶性转化模式的结节,但在DHEA治疗的大鼠中未出现。未用DHEA治疗的8只存活大鼠在第56周时全部发生了癌,而用DHEA治疗的4只存活大鼠中只有1只发生了癌。这些数据表明,DHEA在体内抑制大鼠肝脏和PNs中的G6PD活性。这与PNs的生长抑制相关,并导致其向恶性肿瘤进展的抑制。